Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

This study has been completed.
Sponsor:
Information provided by:
Ironwood Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00258193
First received: November 22, 2005
Last updated: October 19, 2006
Last verified: October 2006
  Purpose
  • The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS.
  • The secondary objectives of this trial are:

    1. To compare the dose ranging pharmacodynamic effects of placebo, and 100 and 1000 ug MD-1100 Acetate once daily on time to first bowel movement after first drug intake.
    2. To describe and summarize the effects of placebo, and 100 and 1000 ug MD-1100 Acetate once daily on stool frequency, stool consistency, ease of passage and sensation of incomplete evacuation during the Treatment Period relative to Baseline.

Condition Intervention Phase
Irritable Bowel Syndrome
Drug: MD-1100 Acetate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Pharmacodynamic Effects of Orally Administered 100ug and 1000ug QD MD-1100 Acetate on Gastrointestinal Transit in Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)

Resource links provided by NLM:


Further study details as provided by Ironwood Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • (Safety) AEs to be collected beginning with patient’s first administration of study medication through final study visit
  • Clinical chemistry, hematology, and urinalyses to be performed before and after the Treatment Period
  • Cardiac safety will be monitored by ECG recordings
  • (Efficacy) Primary endpoints for analysis of efficacy are the colonic geometric center (GC) at 24 hours and ascending colon t1/2 values.

Secondary Outcome Measures:
  • Secondary transit endpoints will be gastric emptying t1/2, colonic filling at 6 hours, colonic GC at additional time points including 48 hours, and time to first bowel movement after the first dose of medication.

Estimated Enrollment: 36
Study Start Date: January 2006
Estimated Study Completion Date: September 2006
Detailed Description:

Using a double-blind, randomized, placebo-controlled, parallel group study design, the effects of placebo and two different doses of orally administered MD-1100 Acetate on gastric emptying, small bowel transit and total colonic transit will be compared and evaluated in patients with C-IBS.

After eligibility is confirmed, the patient will return for baseline measurement of colonic transit to ensure that the transit profile is not greater than the mean transit profile of healthy controls in order to avoid a ceiling effect. A patient must have a geometric center of ≤2.65 at 24 hours, or ≤3.0 at 24 hours and ≤3.9 at 48 hours in order to be randomized to a 5-day Treatment Period of study medication. Eligible patients will receive oral study medication for 5 days during which colonic transit will be measured.

Approximately 36 (n=36) patients will be randomized to one of three different treatment groups: placebo (n=12), 100 ug MD-1100 (n=12), or 1000 ug MD-1100 (n=12). All dosing of study medication will be supervised at the Mayo Clinic.

Patients will complete a daily Stool Diary to record bowel habits for 5 consecutive days during the Pretreatment Period and then for the 5 consecutive days of the Treatment PeriodPhysical examinations, vital signs, electrocardiograms, and clinical laboratory tests will be performed throughout the study and adverse events will be recorded for safety evaluation.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient agrees to use a medically accepted, double-barrier form of contraception (e.g., IUD and condom) during participation;
  • No evidence of pelvic floor dysfunction and the completion of a negative digital rectal exam prior to the first dose of study medication;
  • Absence of an evacuation disorder as defined per protocol;
  • Patients must meet ROME II Criteria for C-IBS;
  • The patient’s Baseline Colonic Transit Test must show a geometric center (GC) ≤ 2.65 at 24 hours, or ≤ 3.0 at 24 hours and ≤ 3.9 at 48 hours.

Exclusion Criteria:

  • History of clinically-significant manifestations of any major system organ class;
  • History of inflammatory bowel disease or gastric ulcers;
  • Significant GI surgery within 6 months;
  • Clinically-significant prolonged diarrhea within 60 days;
  • Special dietary habit and/or an intense physical workout program within 4 weeks;
  • Certain drug hypersensitivities
  • History of alcoholism or drug addiction within 12 months;
  • Receipt of an investigational drug during the study or within 30 days;
  • Use of any prescription medication or OTC, non-prescription medications disallowed by the protocol within 7 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00258193

Locations
United States, Minnesota
Mayo Clinic Foundation
Rochester, Minnesota, United States
Sponsors and Collaborators
Ironwood Pharmaceuticals, Inc.
Investigators
Principal Investigator: Michael Camilleri, MD Mayo Clinic Foundation
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00258193     History of Changes
Other Study ID Numbers: Protocol MCP-103-005
Study First Received: November 22, 2005
Last Updated: October 19, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Ironwood Pharmaceuticals, Inc.:
C-IBS
IBS-C
Constipation-predominant Irritable Bowel Syndrome
Constipation Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
IBS
Transit
Scintigraphy
Gastroenterology
Gastrointestinal
GC
MD-1100 Acetate
MD-1100
linaclotide
linaclotide acetate

Additional relevant MeSH terms:
Constipation
Irritable Bowel Syndrome
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 28, 2014